10x (TXG) Short-Term Debt to Capital
10x Genomics, Inc. (TXG) maintains an impeccable status in the field of spatial biosystem analysis, establishing the foundation for personalized therapy. Price action on the GURU.Markets platform, where the indicator stands at 0.03, reflects the impact of litigation and new competitors on profitability. Meanwhile, the business relies on an integrated suite of hardware and software that strictly locks users into its own proprietary technological ecosystem.
TXG (10xgenomics.com): analytical breakdowns and indicator data
This indicator measures the proportion of short-term liabilities within the equity structure, reflecting the company's dependence on borrowing costs and liquidity risk in the event of changes in regulatory policy. The current value of 0.03 on the short-term debt-to-equity chart allows for an assessment of the financial stability of 10x Genomics, Inc. (TXG), taking into account costs for production outsourcing and cloud infrastructure.